# iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

> **NCT03608631** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 28 (estimated)

## Conditions studied

- KRAS NP_004976.2:p.G12D
- Metastatic Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Stage IV Pancreatic Cancer AJCC v8

## Interventions

- **DRUG:** Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA

## Key facts

- **NCT ID:** NCT03608631
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-27
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03608631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03608631, "iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03608631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*